Takeda Pharmaceutical Company Limited featured 12 presentations, including 11 posters and one oral presentation, at the 15th annual WORLDSymposium™ 2019 in Orlando, Florida, February 4-8.
Takeda Pharmaceutical Company Limited, founded in 1781, is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. The company also makes targeted R&D investments in Plasma-Derived Therapies and Vaccines.
The presentations and other company activities focused on its research and development efforts in lysosomal storage disorders (LSDs) including Hunter syndrome (also known as Mucopolysaccharidosis type II or MPS II), type 1 Gaucher disease, Fabry disease and metachromatic leukodystrophy (also known as MLD).
The WORLDSymposium annual meeting focuses on the latest scientific and clinical research on LSDs, a collection of some 50 disorders caused by specific enzyme deficiencies and leading to significant disability and disease burden.
Included among the presentations was the biobank study:
Study to determine predictive potential of an algorithm for earlier diagnosis of Gaucher disease: Retrospective biobank study utilizing real-world data available in Finland Poster #316
“This year we are pleased to demonstrate that Takeda is committed to supporting the lysosomal storage disorder community and to advancing treatment in areas of high unmet need.” … “We look forward to continuing to participate annually in this unique congress which gives us the opportunity to reconnect and engage with the world’s leading LSD experts and patient organizations, who all share our passion for supporting patients affected by rare disease.” – Hartmann Wellhoefer, M.D., Vice President, Medical Affairs, Rare Disease and Internal Medicine, Global R&D, Takeda.